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Abstract
Retroviral integrases (IN) catalyze the integration of the reverse-transcribed viral DNA into the host genome, an essential process leading
to virus replication. For Moloney murine leukemia virus (M-MuLV) IN, the limited solubility of the recombinant protein has restricted the
development of biophysical and structural analyses. Herein, recombinant M-MuLV IN proteins, either full length or two nonoverlapping
domain constructs, were purified under non-denaturing conditions from solubilized bacterial extracts by Ni2-NTA resins. Additionally, WT
IN was further purified by heparin chromatography. All of the purified proteins were shown to be active and stable. WT M-MuLV IN
chromatographed with a peak corresponding with a dimer by gel filtration chromatography. In contrast, the single point mutant C209A IN
migrated predominantly as a tetramer. For both proteins, fractions in equilibrium between dimers and tetramers were competent to assemble
concerted two-end integrations and yielded a unique strand-transfer profile in the presence of a 28-mer U5 oligonucleotide substrate,
indicative of a distinct conformation within the synaptic complex. This specific target-site selection was not observed with a shorter 20-mer
U5 substrate. These studies provide the foundation for biophysical and structural analysis on M-MuLV IN and the mechanism of retroviral
integration.
© 2003 Elsevier Inc. All rights reserved.
Introduction
An essential step of the retroviral life cycle is the inte-
gration of the reverse-transcribed viral DNA into the host
genome. This two-step process is carried out by the viral
enzyme integrase (IN), encoded by the pol gene. First, two
deoxynucleotides are removed from both 3 termini of the
viral long terminal repeats (LTRs), exposing the conserved
CA at the recessed 3 ends (3-processing) (Brown et al.,
1989; Fujiwara and Mizuuchi, 1988; Katzman et al., 1989;
Roth et al., 1989). The 3 ends of the viral DNA are then
joined to 5 staggered sites in the target DNA in a concerted
transesterification reaction (strand transfer) (Craigie et al.,
1990; Engelman et al., 1991; Katz et al., 1990). Integration
is completed by repair of the 5 overhang of the viral LTR
and the single-strand gaps flanking the integrated viral
DNA, presumably by host enzymes. Repair of the single-
strand gaps creates the hallmark duplication of the target
DNA sequence flanking the retroviral integration site.
Sequence comparison and mutational analysis have iden-
tified three functional domains in the retroviral IN proteins.
The N-terminal domain contains a conserved His-His/Cys-
Cys (HHCC) region (Johnson et al., 1986), which can co-
ordinate a zinc ion in an ordered conformation with in-
creased -helical content (Burke et al., 1992; McEuen et al.,
1992; Yang et al., 1999a). For Moloney murine leukemia
virus (M-MuLV), the HHCC is essential for IN function in
vivo and optimal integration in vitro (Jonsson et al., 1996;
Roth et al., 1990). Biophysical and biochemical analyses
showed that the HHCC domain is involved in protein mul-
timerization (Lee et al., 1997; Yang et al., 1999a; Zheng et
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al., 1996) and it is required for the formation of stable
IN–LTR complexes (Donzella et al., 1996; Engelman et al.,
1993; VanDenEnt et al., 1999; Vink et al., 1994). For
M-MuLV IN, we have previously shown that the isolated
HHCC domain forms dimers in solution (Yang et al.,
1999a). Preincubation of the isolated M-MuLV HHCC do-
main with the LTR substrate increases the efficiency of
two-end concerted integration products, in a complementa-
tion assay with a core/C-terminus IN construct (Yang and
Roth, 2001).
The central core domain of IN is characterized by a
conserved D-D(35)-E triad motif. Mutation of the con-
served aspartic or glutamic acid residues results in loss of all
catalytic activities, indicating a role for these three residues
in active site function (Drelich et al., 1992; Engelman and
Craigie, 1992; Kulkosky et al., 1992; Leavitt et al., 1993).
Solution of crystal structures of isolated catalytic core do-
mains of human immunodeficiency virus type 1 (HIV-1)
and avian sarcoma virus (ASV) IN revealed that the cata-
lytic domains of retroviral INs fold with similar topology
(Bujacz et al., 1995; Dyda et al., 1994). Recently, structures
of the core plus the C-terminus domains of HIV-1 IN (Chen
et al., 2000a) and HIV-1 core with the N-terminal HHCC
domains (Wang et al., 2001) have been solved. In these
models, the catalytic triad is on the outer faces of the dimer.
The C-terminal region is less conserved and has been
demonstrated to possess nonspecific DNA-binding activity
(Khan et al., 1991; Mumm and Grandgenett, 1991; Vink et
al., 1993; Woerner and Marcus-Sekura, 1993). The NMR
structure of the DNA-binding domain of HIV-1 IN appears
as a saddle-shaped dimer (Lodi et al., 1995), and the two-
domain structure with the catalytic core shows flexibility of
the C-terminus domain with respect to the catalytic core
(Chen et al., 2000a, 2000b).
Although the independently folding domains of IN have
been delineated and some of their structures solved, the
manner in which these domains interact to form the cata-
lytically active protein is still not understood. Evidence that
integrase is a multimeric enzyme has been obtained through
direct physical measurement of purified IN, cross-linking
experiments (Gao et al., 2001; Heuer and Brown, 1998), and
in vitro complementation analyses (Engelman et al., 1993;
Jonsson et al., 1996; vanGent et al., 1993; Yang et al.,
1999a; Yang and Roth, 2001). Purified recombinant INs can
exist in a dynamic equilibrium that includes monomers,
dimers, tetramers, and higher-order oligomers (Bao et al.,
2003; Jones et al., 1992; Sherman and Fyfe, 1990; Vincent
et al., 1993). Sedimentation analysis of ASV IN along with
activity assays has revealed that the enzyme is active as a
multimer, minimally a dimer which assembles to a tetramer
in the presence of DNA (Bao et al., 2003; Jones et al.,
1992). For M-MuLV integrase, the limited solubility of the
recombinant protein has impeded structural analyses and
detailed studies of subunit composition.
Multiple strategies have been developed to purify retro-
viral INs due to their limited solubility. The expression and
purification of isolated IN regions have facilitated the bio-
chemical and biophysical characterization of isolated do-
mains. Full-length, recombinant M-MuLV IN proteins re-
quired extraction from insoluble fractions under harsh
denaturing conditions followed by slow refolding schemes
of renaturation (Jonsson et al., 1993). Structural studies of
HIV-1, Rous sarcoma virus (RSV), and simian immunode-
ficiency virus (SIV) INs have been greatly advanced
through the mutational analysis of hydrophobic residues for
improved solubility. For each, one point mutation improved
the solubility and facilitated structural studies, including
F185K for HIV-1 (Jenkins et al., 1996), F199K for RSV
(Hyde et al., 1999), and F185H for SIV (Li et al., 1999).
In this study, recombinant tagged M-MuLV integrase
proteins were purified under nondenaturing conditions from
solubilized bacterial extracts. All of the purified IN proteins
were shown to be active and stable in solution. Size frac-
tionation of wild-type (WT) and a single point mutant
C209A identified multimerization states competent to as-
semble concerted two-end integrations. These studies pro-
vide the foundation for structural analysis on M-MuLV
integrase and retroviral integration.
Results
M-MuLV IN constructs
A schematic representation of the M-MuLV IN and mu-
tants utilized in this study is shown in Fig. 1A. Previous
work in our laboratory has shown functional complementa-
tion between two nonoverlapping IN domains, consisting of
the HHCC domain (IN 1-105) and the core/C-terminal re-
gion (IN 106-404) (Yang et al., 1999a; Yang and Roth,
2001). Recombinant, purified C209A IN is active using in
vitro oligonucleotide-based assays (Jonsson et al., 1996);
however, in vivo, passage of virions bearing IN C209A are
extremely delayed (Donzella et al., 1998). Modification of
Cys209 with N-ethylmaleimide (NEM) blocked IN function
and complementation with IN 1-105. C209A IN was insen-
sitive to modification with NEM (Donzella et al., 1998) and
resulted in the loss of complementation with IN 1-105
(Jonsson et al., 1996). M-MuLV C209A IN was included in
these studies due to the implication of the central cysteine
residue in IN multimerization.
Studies of the HIV-1 (Jenkins et al., 1996), RSV (Hyde
et al., 1999), and SIV (Li et al., 1999) IN proteins have been
greatly advanced through the mutational analysis of hydro-
phobic residues for improved solubility. The Genthreader
program (Jones, 1999) was applied to align and thread the
M-MuLV IN against a known IN structure for steric anal-
ysis. By this approach, A252 within M-MuLV IN was
identified as the equivalent to HIV-1 IN F185, and N254
was found to be equivalent to RSV IN F199 (data not
shown). These residues were targeted for mutagenesis (Fig.
1A): Ala252 was replaced by His and Lys; N254 was
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mutated to Lys. Additionally, a third substitution was gen-
erated within a region of high hydrophobicity to replace
Leu244 to Gln.
Characterization of M-MuLV IN and mutants from the
soluble fraction
Fig. 2 shows a schematic of the expression and purifi-
cation procedure utilized to obtain purified WT M-MuLV
IN from solubilized bacterial extracts. A similar approach
has been recently used to express and purify HTLV-2 IN
(Pieper and Jonsson, 2002) and the Sin Nombre virus N
protein (Jonsson et al., 2001), a member of the hantavirus
genera, family Bunyaviridae. Overnight bacterial cultures
were diluted and induced with IPTG for 2 h at 30°C.
Bacterial pellets were resuspended in a solubilization buffer
containing 300 mM NaCl and 10 mM of the zwitterionic
Chaps detergent. Bacterial lysis was triggered at 4°C by
lysozyme, Dounce homogenization, and extensive but con-
trolled sonication cycles at 4°C. Sonication in the presence
of Chaps and high salt released IN proteins from cellular
nucleic acid into a soluble fraction. The soluble fraction was
clarified by centrifugation and analyzed for solubility or
subjected to further purification as discussed below.
Analysis of the solubility of WT and mutant M-MuLV IN
Four mutations, A252H, A242K, N254K, and L244Q,
were introduced into M-MuLV IN within the region homol-
ogous to that which resulted in increased solubility for the
HIV-1 (Jenkins et al., 1996), RSV (Hyde et al., 1999), and
SIV (Li et al., 1999) IN proteins (Fig. 1A). The solubility of
these four point-mutant proteins and C209A IN were com-
pared to that of the WT IN protein in the context of the
current solubilization conditions. Cultures were induced
with IPTG and lysed, and soluble fractions were obtained
under conditions similar to those for purifying the wild-type
protein (Fig. 2). A representative Western blot of SDS–
Fig. 1. (A) Illustration of IN proteins used in this study. The name of each construct is indicated to the left of each protein. (B) Solubility of the point mutants
generated on the full-length M-MuLV IN protein; 0.005% of the soluble fraction (1 mL) for each mutant protein was loaded on SDS–PAGE and analyzed
by Western blotting with anti-IN antibody (Tanese et al., 1986). Migration of molecular weight markers are indicated.
Fig. 2. Purification scheme. Major steps in order to obtain soluble fraction
are shown. Below, the two procedures to obtain purified M-MuLV IN
proteins. Left: Proteins bound to Ni2-NTA beads are eluted with the
indicated solutions of imidazole. Right: Proteins bound to Ni2-NTA
column/FPLC system are eluted with an imidazole gradient running be-
tween the indicated concentrations. Pooled proteins are then loaded into a
heparin column/FPLC system and eluted with a NaCl gradient running
between the indicated concentrations.
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PAGE of the soluble fractions from the different mutants
and the parental WT IN is shown in Fig. 1B. The 45-kDa
protein corresponding to M-MuLV IN was visible in the
soluble fraction and induced in the presence of IPTG (com-
pare control pET11C (lane 1) to WT IN (lane 7)). The
45-kDa protein detected in the L244Q, A252H, A252K, and
N254L IN mutants was comparable to the WT IN (lanes
2–5). Interestingly, the migration of IN A252H was altered
compared to the related IN A252K substitution (compare
lane 4 to lane 3). A small increase in the level of 45-kDa IN
was detected in the soluble fraction of C209A IN when
compared with that of the WT IN protein (compare lanes 6
and 7). This was further analyzed in a large-scale purifica-
tion of the proteins (see below). Western blot analysis iden-
tified two additional faster migrating species. These are
predicted to be N-terminal truncations, as they did not bind
to Ni2 NTA affinity columns (see below).
Purification of M-MuLV IN and subdomains from the
soluble fraction
The soluble fraction was isolated after clarification by
centrifugation and was subjected to two different purifica-
tion schemes, one utilizing batch purification and the other
FPLC column chromatography (Fig. 2). In order to obtain
highly purified full-length IN protein, the soluble fraction
was applied to a Ni2-NTA resin column using a FPLC
system (Fig. 2, right). After washing the column, proteins
were eluted with a linear imidazole gradient. Fractions were
subjected to SDS–PAGE and assayed for strand-transfer
activity. This assay uses a 5-labeled oligonucleotide sub-
strate mimicking the U5 LTR terminus, which lacks the two
terminal bases removed during 3-processing, thus exposing
the 5-CA-3 end, as illustrated in Fig. 3A. A representative
profile of activity of the eluted fractions from the Ni2-NTA
column is shown in Fig. 4A. The predominant protein de-
tected within the peak of integrase activity (fractions 21–25)
was the 45-kDa IN product, visualized by Coomassie stain-
ing (Fig. 4A, lower panel). The peak of strand-transfer
activity corresponded with 100 mM imidazole. Although
the bulk of eluted IN protein shows a significant level of
purification, pooled fractions were subjected to further pu-
rification through a FPLC–heparin resin. Bound proteins
were then subjected to elution by a linear gradient of NaCl
(0.4–2 M, Fig. 2) and fractions were assayed by strand-
transfer activity and SDS–PAGE of the fractions. A repre-
sentative column profile of WT IN activity is shown in Fig.
4B. There is a sharper peak of strand-transfer activity (i.e.,
fractions 12–18, upper panel) at 1.1 M NaCl which corre-
lates with the elution of the protein as visualized by Coo-
massie staining (i.e., fractions 12–19, Fig. 4B, bottom
panel). Furthermore, a smaller protein contaminant eluted
prior to the 45-kDa IN protein peak. The active WT IN
fractions were pooled giving a yield of 0.83 mg of highly
purified active protein per liter of induced bacterial culture.
Rapid purification of multiple constructs was obtained
using batch purification on Ni2-NTA. Fig. 4C summarizes
the purified fractions of IN 1-105, IN 106-404, C209A IN,
and WT IN. Fractions were bound in batch to Ni2-NTA
and eluted at 50, 100, 250, and 500 mM imidazole steps.
Fractions were pooled based on purity across the individual
steps. For IN 1-105 (Fig. 4C, lane 1), C209A IN (Fig. 4C,
lane 3), and WT IN (Fig. 4C, lane 4), fractions were pooled
from the 50 and 100 mM imidazole steps. For IN 106-404,
the fractions were pooled from the 50–250 mM steps (Fig.
4C, lane 2). Two additional proteins of Mr 26,000 and
15,000 are detected in the IN 106-404 preparation. The
15-kDa protein was recognized by anti-IN antibodies on
Western blot (data not shown) and therefore represents a
low level of breakdown product. Starting from 1 L of
Fig. 3. (A) Integration assays based on oligonucleotide 5-labeled substrates. 3-processing and strand-transfer reactions are indicated. (B) Concerted two-end
integration assay. Target DNA and the two major types of reaction products are shown. The third product (not indicated) is identical to that shown in (A).
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Fig. 4. Activity column profiles from Ni2-NTA/FPLC (A) or from heparin column/FPLC system (B). Fractions were assayed for strand-transfer activity
(upper panels) and SDS–PAGE and Coomassie staining (lower panels). (C) M-MuLV IN proteins purified using batch elution. Lane 1, IN 1–105; lane 2, IN
106–404; lane 3, C209A IN; lane 4, WT IN.
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induced cultures, this purification scheme yield 3 mg of IN
1-105, 1.65 mg of IN 106-404, 0.3 mg of C209A IN, and
0.15 mg of WT IN. These fractions were suitable for the
biochemical studies on the M-MuLV IN proteins presented
below.
Catalytic properties of the purified IN proteins
Functional complementation between two nonoverlap-
ping fragments of M-MuLV IN, the HHCC N-terminal
domain (IN 1-105), and the core/C-terminal region (IN
106-404) is observed in vitro (Yang et al., 1999a; Yang and
Roth, 2001). The purified IN proteins used for those studies
were extracted from the insoluble fractions followed by
slow steps of renaturation (Jonsson et al., 1993). To exam-
ine the activity of the protein subdomains purified from the
soluble fraction, the activity of the nonoverlapping domains
was determined in a complementation assay for the 3-
processing reaction. In this assay, a 20-mer 5-labeled blunt-
ended oligonucleotide mimicking the terminal U5 at the
LTR is used as the substrate for the reaction (Fig. 3A). Upon
resolution of the products on denaturing electrophoresis,
both a 2 processed product migrating larger than the input
substrate and heterogeneous sized strand-transfer products
migrating larger than the input substrate can be visualized.
Fig. 5A shows a complementation assay in which the cat-
alytic subunit of IN (IN 106-404) was held constant with a
titration of the N-terminal domain (IN 1-105) in the reac-
tion. No products were detected in the absence of enzyme
(Fig. 5A, lane 1) or in the presence of IN 106-404 alone
(Fig. 5A, lane 3). Upon addition of the HHCC domain (for
a molar ratio IN 1-105:IN 106–404 of 2.3), both the 3-
processing and the strand-transfer products can be visual-
ized (Fig. 5A, lane 4). Higher levels of the HHCC domain
in the reaction inhibited catalysis (lanes 5–9). Optimal ac-
tivity was observed at 10 mM MnCl2 and 100 mM of KCl.
A low level of strand-transfer activity was observed in 1
mM of MgCl2 (data not shown).
The catalytic activity of the nonoverlapping IN frag-
ments was also assayed for concerted two-end integration
(Yang and Roth, 2001). In this assay, the 5-labeled pre-
cleaved oligonucleotide substrate is used as the donor DNA
and a circular plasmid is the target DNA for integration
(Fig. 3B). Two different length U5 oligonucleotide mimics
were assayed: a 20-mer and a 28-mer (Fig. 5B). The IN
1-105 domain was titrated against 1 pmol of IN 106-404.
Reaction products were resolved by agarose gels (Fig. 5B)
and quantified (Fig. 5C). The efficiency of both one-end and
two-end integration reactions is reproducibly increased
four- to fivefold in the presence of the 28 versus the 20-mer
Fig. 5. Complementation assays of purified IN 1–105 and IN 106–404. (A) 3-processing and strand-transfer reactions using 0.5 pmol of a blunt-end
20-mer-labeled oligonucleotide-based assay. IN 106–404 (1 pmol) was incubated alone (lane 3), or in the presence of IN 1–105 at 2.3 pmol (lane 4), 4.6
pmol (lane 5), 9.2 pmol (lane 6), 13.8 pmol (lane 7), 27 pmol (lane 8), and 55 pmol (lane 9). Products were resolved by 16% sequencing gels. Lanes 1 and
2 correspond to reactions in the absence of presence of 5 pmol of purified WT IN protein, respectively. (B) Concerted two-end integration assay; 1 pmol of
IN 106–404 IN was assayed with increasing amounts of IN 1–105 using a 20-mer (lanes 1–7) or with a 28-mer (lanes 8–14) donor-labeled substrate and
a target DNA. Reactions products were resolved by agarose gels and the radioactive bands quantified as shown in (C).
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substrate (compare panels 20-mer and 28-mer, Fig. 5C).
This result suggests that longer substrates promote a more
efficient assembly of a catalytic competent complex and/or
further stabilize the interactions between the domains. This
is of interest, as the region between positions 20 and 28 is
outside of the conserved 13-bp inverted repeat sequence at
the termini of the LTR.
Despite the efficiency differences between the 20-mer
and the 28-mer U5 LTR substrate, the single-end and the
two-end products were similar with respect to the ratios of
IN 1-105 to IN 106-404. Preferential synthesis of two-end
integration products was observed at an IN 1-105:IN 106-
404 ratio of 2:1 (lanes 3 and 9, Fig. 5B). At a molar ratio IN
1-105:IN 106-404 of 3:1, the overall yield of products
increased; however, the ratio of one-end:two-end integra-
tion was near stoichiometric (Fig. 5C). The two-end inte-
gration products were more sensitive to the presence of
excess of IN 1-105 zinc-binding domain (Fig. 5B, lanes 5
and 11). The presence of a large excess of IN 1-105 (28-fold
molar excess over IN 106-404, Fig. 5B, lanes 6 and 12) was
inhibitory to the two-end integration reaction.
The catalytic activities of the full-length, wild-type IN
protein purified under the current scheme were also ana-
lyzed. Fig. 6A shows a titration of WT IN (1.4 to 10 pmol)
in the presence of 0.5 pmol of a blunt-ended 20-mer oligo-
nucleotide substrate. Maximal 3-processing was observed
with 5 pmol of IN enzyme (lane 6), and increasing the
amount of enzyme to 7.6 pmol or higher yielded inhibition
of both 3-processing and strand-transfer reactions (Fig. 6A,
lanes 7 and 8).
The full-length IN enzyme was also tested in the con-
certed two-end integration assay (Fig. 6B). The WT IN was
titrated for strand transfer into a plasmid target DNA using
a 5-labeled precleaved oligonucleotide substrate, and the
products were analyzed by agarose gels. The yield of one-
end and two-end products increased with respect to IN
protein (lanes 1–3), with maximal products detected at 5
pmol enzyme in the presence of 1 pmol of 28-mer U5 LTR
substrate (lane 4). Concentrations of enzyme over this
amount inhibited both the one-end and the two-end strand-
transfer products (lanes 5 and 6). Although the one-end
integrant remains the preferred product, the yield of two-end
concerted integrants is improved utilizing the protein puri-
fied from the soluble fraction.
Characterization of soluble M-MuLV IN by size-exclusion
chromatography
To determine the multimerization state of M-MuLV IN,
the WT and C209A IN were further characterized by size-
exclusion chromatography. Within M-MuLV IN, there are
three Cys residues; two within the zinc-binding domain and
the third, C209, within the catalytic core. Previous studies
have shown that IN 106-404 bearing C209A was unable to
complement IN 1-105, indicating that the mutation affected
the multimerization of IN (Jonsson et al., 1996). IN C209A
was therefore analyzed by size fractionation. The soluble
fraction of WT IN and C209A (Fig. 2) was purified by
Ni2-NTA affinity columns, eluted with step concentrations
of imidazole, and pooled. WT IN and C209A IN were
further concentrated and applied into a FPLC S200 size-
exclusion column. The elution profiles are shown in Fig.
7A. The elution position of the globular protein markers is
indicated. No proteins were found in the void volume of the
column (data not shown). WT IN protein eluted in a broad
protein profile with a major peak between 150- and 66-kDa
protein markers. From the standard curve, the calculated
molecular mass of the predominant WT IN species was 95
kDa, corresponding to a dimer of WT IN. C209A IN protein
eluted in a more limited profile with a major peak between
443- and 150-kDa protein markers, corresponding to a cal-
culated molecular mass of 165 kDa, consistent with a tet-
ramer of C209A IN.
Fractions from the S200 column were further analyzed
for integration activity. Equivalent aliquots of the fractions
containing IN proteins were incubated with a precleaved
5-labeled 28-mer oligonucleotide substrate and strand-
transfer products into a plasmid DNA target were analyzed
by agarose gels (Yang and Roth, 2001). Fig. 7B shows the
profile of concerted strand-transfer activity from the frac-
Fig. 6. Integration assays of purified M-MuLV IN. (A) 3-processing and
strand-transfer reactions in an oligonucleotide-based assay; 0.5 pmol of
blunt-end-labeled 20-mer substrate was incubated with increasing amounts
of purified IN: 1.26 pmol (lane 3), 2.52 pmol (lane 4), 3.8 pmol (lane 5),
5 pmol (lane 6), 7.6 pmol (lane 7), and 10 pmol (lane 8). Reaction products
were resolved on 16% sequencing gels, dried, and exposed. (B) Concerted
two-end integration; 1 pmol of a 28-mer-labeled substrate was incubated
with increasing amounts of purified WT IN: 0.63 pmol (lane 1), 1.26 pmol
(lane 2), 2.52 pmol (lane 3), 5 pmol (lane 4), 7.6 pmol (lane 5), and 10
pmol (lane 6) and with the target DNA for 1 h at 37°C. Reaction products
were resolved by 1% agarose gels and the dried gels exposed to films.
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tions containing the WT IN protein. Although further as-
sembly of protein and DNA occurs under the assay condi-
tions, analysis across the S200 column identifies IN
multimerization states capable of functional assembly. The
peak of concerted strand-transfer activity is located between
fractions 52 and 54 with a maximum yield obtained from
fraction 53. Low strand-transfer activity was detected when
the input IN into the assay consisted of fractions expected to
contain tetramers (Fig. 6B, fraction 50) or those expected to
contain monomers of WT IN (Fig. 7B, fraction 59) (data not
shown). A profile of concerted strand-transfer activity of the
fractions containing the C209A IN protein is shown in Fig.
7C. The peak of strand-transfer activity is concentrated
between fractions 49 and 53 with a maximum yield obtained
from fraction 50, consistent with the structure of the input
C209 IN of a tetramer. C209A IN fractions predicted to
contain IN dimers maintained significant levels of activity
for this assay (Fig. 7C, fraction 53). Fractions expected to be
monomers are not active (fraction 59, data not shown).
Fractions resolved by exclusion chromatography were
further analyzed in the oligonucleotide-based assays (Fig.
3A). Initial assays utilized a 20-mer precleaved substrate
(Fig. 8A), and limiting amounts of the fraction (1 l) were
assayed for strand transfer. The profile of activity from
fractions containing WT IN protein is shown in Fig. 8A. A
single peak of strand-transfer activity at fraction 50 was
detected under these conditions. These results suggest that
under limiting enzyme, preassembled tetramers are active
for strand transfer, under conditions where preassembled
dimers present at higher concentrations (fraction 53) are not
active.
Strand-transfer activity with S200 fractions was further
tested using a longer 28-mer precleaved substrate and the
products were visualized by denaturing electrophoresis
(Figs. 8C and D). Interestingly, two different patterns of
target-site utilization were observed for the strand-transfer
products. For the WT IN S200 fractions, there is a loss of a
high-molecular-weight strand-transfer product from frac-
tions 51 to 54 (Fig. 8C). This corresponds to fractions
whose input IN was capable of concerted two-end integra-
tion with an exogenous plasmid target DNA (Fig. 7B). The
large strand-transfer products result from integration at the
end of the target DNA. These results indicate that the
assembly of an active synaptic complex on a large target
DNA within these fractions is distinct. The generation of
different target sites was previously detected in complemen-
tation assays using IN 106-404 and IN 1-105. A limited
range of target sites were selected in the presence of a
zinc-coordinated HHCC region versus a HHCC domain
renatured in the presence of EDTA (Yang et al., 1999a). The
increase in stringency was interpreted to reflect the tightness
of the assembled complexes in presence of Zn2.
Similarly, two different patterns of strand-transfer prod-
ucts can be visualized when aliquots of fractions containing
C209A IN mutant are assayed utilizing the 28-mer U5 LTR
oligonucleotide (Fig. 8D). A shift to higher-molecular-
weight strand-transfer products is observed between frac-
tions 48 and 52, whose input IN is in the range of dimers
and tetramers. These fractions directly correlate with those
active for integration into a large exogenous DNA substrate
(Fig. 7C). Fractions 44 to 47 (including multimers greater
than tetramers) plus fractions 55 to 64 (including mono-
mers) yield smaller sized strand-transfer products. Although
similar fractions were positive for strand-transfer activity
Fig. 7. Chromatographic resolution of M-MuLV integrase proteins. (A) Elution profile of WT IN and C209A IN on S200 gel filtration chromatography. The
relative position of migration of the globular molecular weight markers is indicated. The volume of each fraction was 275 L. Inset: Migration is plotted
vs the molecular weight of the markers. Dotted lines show molecular weight of fractions 50 and 53. The profile shows only fractions containing proteins.
Aliquots (1 L) of the fractions of WT IN (B) or C209A IN (C) were assayed in the concerted two-end integration assay, using a 28-mer 5-labeled
oligonucleotide donor substrate and target plasmid DNA as acceptor.
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using a 20-mer substrate (Fig. 8B), no difference in the
target-site specificity was observed. The result using the
28-mer was surprising. The generation of a different target
site may represent a distinct conformation of the DNA
within an active synaptic complex.
Discussion
In this study, we have purified active M-MuLV integrase
proteins under nondenaturing conditions. Recombinant M-
MuLV IN was previously purified under harsh denaturing
conditions involving highly concentrated solutions of either
guanidine chloride or urea to solubilize the proteins from
inclusion bodies (Jonsson et al., 1993), causing protein
denaturation. Slow renaturation by dialysis is necessary
after purification, in order to refold the protein into an active
conformation. In the current study, IN was solubilized im-
mediately after bacterial lysis, by performing a series of
controlled cycles of sonication at 4°C. The strong DNA-
binding activity of retroviral IN has been previously re-
ported (Roth et al., 1988). After shearing the DNA, solubi-
lized IN can be directly bound to nickel-affinity resins,
eluted with imidazole solutions, and further purified by
heparin columns. A similar scheme of lysis was previously
used to purify GST-tagged M-MuLV IN by using gluta-
thione–agarose resins (Dotan et al., 1995). In that report, for
consistent activity between different preparations, a phos-
phocellulose column was necessary to remove an inhibitor
(Dotan et al., 1995). Using the purification scheme de-
scribed herein, individual fractions eluted with imidazole
could be directly monitored for IN activity. A similar
scheme of lysis and solubilization was used to purify an
active two-domain derivative of RSV IN (Yang et al.,
1999b), feline immunodeficiency virus (FIV) IN (Shibagaki
et al., 1997), HTLV-2 IN (Pieper and Jonsson, 2002), and
Fig. 8. (A, B) Strand-transfer activity of the S200 chromatography fractions using a 20-mer oligonucleotide substrate. (A) Activity profile of WT IN assayed
at 1 L across the fractions. (B) Activity profile of C209A IN assayed at 2 L across the fractions. Reaction products were resolved by 16% sequencing
gels. (C, D) Strand-transfer activity of the exclusion chromatography fractions using a 28-mer oligonucleotide substrate. WT IN was assayed using aliquots
(2 L) of the fractions (C) or C209A IN (C). Reaction products were resolved by 16% sequencing gels.
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Sin Nombre virus N protein (Jonsson et al., 2001). Other
alternative approaches to purify retroviral INs include sol-
ubilization from insoluble fractions with 1 M NaCl solu-
tions for HIV-1 IN (Sherman and Fyfe, 1990) and RSV PrA
IN (McCord et al., 1998).
Retroviral INs have been modified by site-directed mu-
tagenesis in order to improve their solubility. In an HIV-1
IN study, 29 point mutants were tested in which hydropho-
bic residues were substituted with Lys or Ala residues
(Jenkins et al., 1995). The single point mutation of F185K
within the catalytic core improved the solubility of the
HIV-1 polypeptide. A single point mutation of F199K for
the RSV two-domain integrase (Hyde et al., 1999) and
F185H for SIV IN was also found to improve solubility and
the ability to obtain diffraction quality crystals (Li et al.,
1999). Both of these residues are located at the dimer
interface of the catalytic core domain. A similar approach
was developed with an N-terminal truncated construct of
M-MuLV RT, to modify potentially solvent exposed hydro-
phobic residues. Of the substituted enzymes, V433K and
L435K were substantially more soluble in the absence of
detergent than the parental construct and crystals of the
N-terminal truncated M-MuLV L435K RT complexed with
a duplex of DNA oligonucleotides have been obtained (Das
and Georgiadis, 2001). In the present study, we have tar-
geted four positions at the C terminus within the catalytic
domain of M-MuLV IN for mutagenesis. Substituted amino
acids were found to be structurally equivalent to those
previously altered in HIV-1, RSV, and SIV IN that had
improved the solubility of the polypeptides. Additionally,
we used the previously generated M-MuLV IN point mu-
tant, within the catalytic triad C209A IN, which was known
to be active in vitro for 3-processing, strand-transfer, and
disintegration reactions (Donzella et al., 1998; Jonsson et
al., 1996). Among the mutants tested, C209A IN yielded
twofold increase in the soluble fraction with respect to the
parental WT IN. Using the expression and purification
schemes presented herein, active and highly purified C209A
IN is under intense research in order to obtain diffraction
quality crystallization conditions as a model for the full-
length M-MuLV IN structural analysis.
There are several signs that the proteins purified from the
soluble fractions are greatly improved over renatured prep-
arations in solubility and activity. Previously, the renatured
protein did not chromatograph on DEAE, heparin butyl
sepharose, or sephadex 75 as a homogenous peak (Jonsson
and Roth, unpublished results). On many resins, including
Superose 12 columns, the protein never eluted. From the
results presented on Fig. 4B, the native protein fractionated
on the FPLC–heparin column as a symmetric peak. The
stability of both WT IN and C209A IN allowed the frac-
tionation and activity profiles using size-exclusion chroma-
tography. Previously purified preparations of IN 106–404
recovered from the insoluble fraction were sensitive to high
DTT concentrations for full complementation activity with
IN 1–105 (Donzella et al., 1996; Jonsson et al., 1996),
suggesting improper refolding and low stability in solution.
The activities of IN 106–404 varied widely between dif-
ferent preparations and frequently yielded inactive protein.
With the purification conditions developed herein, the abil-
ity to obtain active IN 106–404 has been highly reproduc-
ible.
The irreproducibility of the proteins purified from the
insoluble fraction makes direct comparison difficult with the
current soluble preparations. However, published data on
previously optimized proteins purified from the insoluble
fractions indicate that the soluble IN 1–105, IN 106–404,
and WT IN require, under standard reaction conditions, a
lower protein:protein as well as protein:DNA ratio for 3-
end processing and strand-transfer reactions compared with
the renatured proteins. Previously a 10-fold molar excess of
IN 1–105 to IN 106–404 was required for optimal strand-
transfer and 3-processing (Yang et al., 1999a), whereas a
2.3:1 ratio was optimal for the soluble proteins. Similarly,
concerted two-end integration previously required an opti-
mal molar ratio of IN 1–105: IN 106–404 of 8:1 (Yang and
Roth, 2001), whereas with the soluble protein, a 2:1 ratio
yielded predominantly two-end concerted integration prod-
ucts. Using the soluble wild-type IN, the optimal IN:DNA
ratio was 10:1. Using the same assay, M-MuLV IN protein
purified from insoluble fractions followed by slow steps of
renaturation required a 20:1 ratio of IN:DNA for optimal
integration (Jonsson et al., 1996). Similarly, optimal two-
end integration using a 28-mer LTR was obtained with the
soluble IN at an IN:LTR ratio of 5:1, whereas previously the
maximal integration into an exogenous substrate required a
20:1 IN:LTR ratio, with the predominant product being the
one-end integrant (Yang and Roth, 2001).
In an infected cell, the two ends of the viral DNA must
be integrated into the target host DNA in a concerted reac-
tion, and multiple lines of evidence suggest that integrase
functions as a multimer to act on both DNA ends. As
previously determined, in solution, both RSV and HIV-1 IN
existed as a mixture of monomers, dimers, and tetramers in
equilibrium (Jones et al., 1992; Vincent et al., 1993). Mul-
timerization is stimulated by Zn2 (Lee et al., 1997), Mn2
(Wolfe et al., 1996), and high-molecular-mass complexes
were detected in the presence of fluorescent oligonucleo-
tides and Mg2 (Vercammen et al., 2002). Protein cross-
linking experiments have also shown that IN exists as a
multimer (Heuer and Brown, 1997, 1998). Furthermore,
multimerization during catalysis is implied by studies indi-
cating complementation between HIV-1 IN mutants (En-
gelman et al., 1993; vanGent et al., 1993) and functional
tetramers were deduced from kinetic studies of disintegra-
tion of ASV IN (Bao et al., 2003). The structure of a
full-length retroviral IN is not yet known. However, the
central catalytic core domain and all two-domain fragments
spanning the core plus either the C terminus (Chen et al.,
2000a; Yang et al., 2000) or the N terminus (Wang et al.,
2001) from different retroviruses form dimers in the crystal
structures. Similarly, the structure of the Tn5 transposase
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synaptic complex consists of a dimer subunit (Davies et al.,
2000). Alternatively, tetramers have been isolated from
cells expressing HIV-1 IN (Cherepanov et al., 2003), also
detected under reducing conditions when HIV-1 IN was
analyzed by fluorescence anisotropy decay measurements
(Deprez et al., 2000) and by a Zn2-dependent interaction
that requires the zinc finger motif in the amino-terminal
domain (Lee et al., 1997). Previously, biochemical charac-
terization of M-MuLV IN was restricted due to the limited
solubility of the recombinant protein. In the present study,
the multimerization state of M-MuLV IN was functionally
analyzed. WT IN was shown to migrate predominantly as a
dimer on size-exclusion chromatography, consistent with
other retroviral IN systems. Functional analysis indicated
that fractions in equilibrium between dimers and tetramers
are capable of assembly and catalysis of two viral LTRs into
an exogenous target DNA. No differences were observed in
the target-site selection of the strand-transfer products when
a 20-mer U5-end substrate was assayed across the gel fil-
tration column. Significant differences in the target-site se-
lection were observed when the column was assayed with a
28-mer U5 substrate for strand transfer. With both 20-mer
and 28-mer U5 substrates, multimers larger than tetramers
and smaller than dimers were shown to be active as well.
However, the dimers and tetramers could be differentiated
from the other multimers in an assay by a distinct strand-
transfer profile and target-site selection, indicative of a dif-
ferent assembly pathway. Similar results were obtained
when fractions containing C209A IN were assayed. Al-
though C209A IN migrated predominantly as a tetramer, the
peaks of activity were also mainly concentrated on fractions
expected to contain dimers–tetramers. These results indicate
that multimerization mediated by protein–protein interac-
tions is different than functional multimerization during
catalysis, in the presence of a DNA substrate.
The first step in the integration pathway involves the
assembly of a stable complex between IN and the viral
DNA donor substrate. HIV-1 IN assembled on immobilized
substrates was shown to be sufficient to catalyze strand
transfer when the target DNA was added subsequent to
assembly (Wolfe et al., 1996). Studies using the HIV-1 IN
strand-transfer inhibitors diketo acids (DKAs) indicated that
the target DNA requires a configuration of the enzyme
defined only after the assembly of the specific IN complex
(Espeseth et al., 2000). The results presented in Fig. 8
suggest that upon assembly on identical 28-mer oligonucle-
otide DNA substrates, the target DNA can be positioned
within the active complex in at least two distinct configu-
rations, as revealed by their distinct target DNA site selec-
tion. Using the same donor 28-mer U5 DNA substrate but a
large plasmid DNA (Fig. 7B), we demonstrated that the
same fraction which migrated on the S200 as dimers
through tetramers were able to perform concerted integra-
tion, which is indicative of a functional and coordinated
nucleoprotein assembly. Previous results have indicated that
plasmid target DNA can access the target binding site and
promote the functional and coordinated assembly of the
multimer, stabilizing the subunits, in a concerted integration
assay (Yang and Roth, 2001). Fractions other than dimers–
tetramers were not correctly stabilized by the plasmid target
DNA since no strand transfer on the exogenous plasmid
could be detected. Substrate coordination features were also
analyzed with M-MuLV disintegration reactions (Donzella
et al., 1996). Mispairing of the crossbone single-strand
region of the substrate affected the intermolecular, but not
the intramolecular disintegration reactions, suggesting dif-
ferential assembly for cis or trans half-site modes of sub-
strate binding (Donzella et al., 1996). It is not known
whether these different configurations are ultimately defined
by protein–protein and/or DNA–protein interactions. As
proposed by Sinha et al. (2002), within the population only
a minority of the HIV-1 IN subunits will correctly interact
to form a nucleoprotein complex competent for concerted
integration. Most of the interactions will lead to one-end
integration events.
The analysis of complementation assays of IN 1-105
with IN 106-404 M-MuLV IN nonoverlapping constructs
indicated a more efficient assembly of multimeric com-
plexes (four- to fivefold) when using 28-mer versus 20-mer
oligonucleotide substrates mimicking the viral terminal U5
in a concerted integration reaction (Fig. 5B). Interestingly,
positions 20 to 28 are outside of the conserved 13-bp in-
verted repeat sequences at the termini of the M-MuLV LTR.
For HIV-1 IN, the extension of 13 nucleotides on the 15
terminal bases IN recognition sequence enhanced 3-pro-
cessing of the termini in an oligonucleotide-based assay
(Vink et al., 1991). Reconstitution systems have also used
purified IN and linear retrovirus-like LTRs to recapitulate
concerted two-end integration reactions (about 500-bp-
long) for HIV-1 (Hindmarsh et al., 1999) and RSV (McCord
et al., 1998). For RSV, as well as in vivo for HIV-1 (Brown
et al., 1999) and M-MuLV (Murphy and Goff, 1992), de-
letions or modifications of internal sequences (up to 12
nucleotides from the end) have major effects in avian LTRs
to promote two-end integration in vitro (Chiu and Grand-
genett, 2000). The role of either the sequence or the struc-
ture of nucleotides outside of the terminal sequences is not
clear. A 22-bp deletion starting at position 12 from the
M-MuLV LTR end has little effect on IN-associated prop-
erties in the preintegration complexes (Wei et al., 1998). For
SIV IN, two-end integration events showed an increase in
efficiency with an increase in the length of the donor DNA
from 134 to 433 bp (Goodarzi et al., 1999). For HIV-1,
positions 17–20 were found to be required for concerted
integration (Brin and Leis, 2002). However, preliminary
results indicate that position 20 of the M-MuLV U5 sub-
strate tolerates any nucleotide when assayed in the comple-
mentation assay for concerted integration (data not shown).
More studies are necessary to define the role of the outside
sequences in recognition by retroviral integrases.
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Material and methods
Materials
Crude [-32P]ATP (7000 Ci/mmol) was purchased from
ICN. T4 polynucleotide kinase, T4 DNA ligase, Vent DNA
polymerase and restriction enzymes were obtained from
New England Biolabs. Ni2-nitrilotriacetic acid agarose
(Ni2-NTA) was purchased from Qiagen. Ni2-NTA Su-
perflow (5 mL) and HiTrap heparin HP (5 ml) were pur-
chased from Amersham Biosciences.
Oligonucleotides
DNA oligonucleotides were prepared by the University
of Medicine and Dentistry of New Jersey, DNA Synthesis
Facility and purified by electrophoresis on 20% denaturing
polyacrylamide gels (Jonsson et al., 1993). Oligonucleo-
tides used in this study were labeled with [-32P]ATP by a
kinase reaction as previously described (Jonsson et al.,
1993). Oligonucleotide 5319 (28-mer) 5-GACTACCCGT-
CAGCGGGGGTCTTTCATT-3 and its complementary
strand 5321 5-AATGAAAGACCCCCGCTGACGGGTA-
GTC-3 or oligonucleotide 2783 (20-mer) 5-GTCAG-
CGGGGGTCTTTCATT-3 and its complementary strand
2785 5-AATGAAAGACCCCCGCTGAC-3 were used as
the blunt-end U5 end substrate for the 3-processing reac-
tions. Oligonucleotide 5320 (26-mer) 5-GACTACCCGT-
CAGCGGGGGTCTTTCA-3 and its complementary strand
5321, or oligonucleotide 2784 (18-mer) 5-GTCAGCG-
GGGGTCTTTCA-3 and its complementary oligonucleo-
tide 2785 mimicking a precleaved U5 end, were used as the
substrate for strand-transfer and two-end integration reac-
tions.
Generation of IN point mutants
Point mutations in M-MuLV IN were generated by over-
lapping PCR. For the oligonucleotides shown below, under-
lined positions indicate the codon changed. For individual
PCR reactions, the first fragment was obtained with a com-
mon 5 primer 5-GATCACCGGTTTTCATTACACAGT-
GACTGATA-3 (100 pmoles) and with 5-CAGGGCTA-
AGGGGAGTTGGAGCACCCAGTCTCT-3 (for L244Q,
100 pmol), 5-GCCCGGCGTGTTGCGCTTTCGGTACA-
GGGCTA-3 (for A252K, 100 pmol), 5-GCCCGGCGT-
GTTGCGGTGTCGGTACAGGGCTA-3 (for A252H, 100
pmol) or 5-ATGGGGGCCCGGCGTCTTGCGGGCTGC-
GTACAG-3 (for N254K, 100 pmol) on the template pET-
HTWT (Jonsson et al., 1993) and Vent DNA polymerase.
Cycle conditions were as follows: 2 min at 95°C, 35 cycles
of 30 s at 95°C, 30 s at 63°C and 90 s at 68°C, and a final
incubation of 10 min at 68°C. A 750-bp fragment in each
case was gel-isolated. The second PCR fragment was ob-
tained with 5-AGAGACTGGGTGCTCCAACTCCCCT-
TAGCCCTG-3 (for L244Q, 100 pmol), 5-TAGCCCTG-
TACCGAAAGCGCAACACGCCGGGC-3 (for A252K,
100 pmol), 5-TAGCCCTGTACCGACACCGCAACACG-
CCGGGC-3 (for A252H, 100 pmol), or 5-CTGTACCG-
AGCCCGCAAGACGCCGGGCCCCCAT-3 (for N254K,
100 pmol), each one incubated with a common 3 primer
5-GGTGGATCCAGTACTGACCCCTCTG-3 (100 pmol)
using template pET-HTWT and Vent DNA polymerase as
described above. A 500-bp fragment in each case was gel-
isolated. For overlapping PCR reactions, equimolar
amounts of the 750 bases fragment and 500 bases fragment
for each mutant were incubated with the 5 and 3 common
primers (100 pmol each) and Vent DNA polymerase. Cycle
conditions were as follows: 2 min at 95°C, 35 cycles of 30 s
at 95°C, 30 s at 53°C, 3 min at 68°C, and a final incubation
of 10 min at 68°C. The 1.2-kb product fragments were
digested with SacII and BamHI (contained within 3
primer). For each construct, an 890-bp fragments was gel-
isolated and exchanged into pET-HTWT. Introduction of
the single point mutations were verified by sequencing with
the 3 common primer at the Core DNA Facility, UMDNJ/
RWJMS.
Expression and purification of M-MuLV integrase
Previously reported expression vectors for recombinant
M-MuLV IN (pET-HTWT wild type) (Jonsson et al., 1993),
IN C209A (Jonsson et al., 1993), IN 106-404 (Jonsson et al.,
1993), and IN 1-105 (Yang et al., 1999a) containing a
hexahistidine tag were expressed in Escherichia coli BL21
(DE3) (Novagen). A similar procedure has been recently
reported for HTLV-2 IN (Pieper and Jonsson, 2002). For
each construct, 100 mL of Luria broth medium (LB) con-
taining 200 g/mL Carbenicillin (LB-Carb200) was inocu-
lated and grown overnight at 37°C with constant shaking.
Cultures were then centrifuged, resuspended into 20 mL of
LB-Carb200, and used to inoculate 1 L of LB-Carb200 in a
2-L flask. Cultures were grown for 2 h at 30°C, induced
with IPTG (0.256 mM) for 2 h at 30°C, and resuspended
into 40 mL of ice-cold solubilization buffer (50 mM sodium
phosphate buffer, pH 8.0, 300 mM NaCl, 10 mM imidazole,
10 mM Chaps (3-[(3-cholamidopropyl)dimethylammonio]-
1-propane sulfonate), 1 protease EDTA-free tablet (Boehr-
inger Mannheim) per 50 milliliters of buffer, at 4°C. One
hundred milligrams of lysozyme was added, dounced until
mixed, and kept at 4°C for 15 min. Samples were then
sonicated for 15 s and placed on ice for 1 min. Sonication
was repeated until samples appeared clear (not viscous) and
then they were centrifuged at 16,000 rpm in a Sorvall SS34
rotor for 1 h at 4°C. Supernatants containing soluble IN
proteins were subjected to purification either by batch pu-
rification or using columns on FPLC systems.
(i) Batch purification
Solubilized extracts (40 mL) were mixed with 1 mL of
Ni2-NTA preequilibrated in solubilization buffer, and in-
cubated overnight at 4°C with rocking. Decanted resin was
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washed with 100 mL of washing buffer (50 mM sodium
phosphate, pH 8.0, 1 M NaCl, 25 mM imidazole, 10 mM
Chaps, 10 mM 2-mercaptoethanol, 20% glycerol). Step elu-
tion (1-mL fractions) was performed with 5 mL each of
washing buffer containing 50, 100, 250, 500 mM imidazole.
Elution of the specific IN proteins and subdomains varied
between 50 and 250 mM imidazole, as indicated. IN pro-
teins or subdomains after one round of batch purification
were active and suitable for biochemical studies. Fractions
were pooled and dialyzed against 20 mM Hepes, pH 7.4, 1.5
mM DTT, 400 mM KCl, 2 mM Chaps, 50% glycerol, and
10 M ZnCl2 and stored at 80°C.
(ii) FPLC-based purification
Five milliliters of Ni2-NTA column–FPLC was sequen-
tially equilibrated with 7 column volumes of buffer A (50
mM sodium phosphate, pH 8.0, 1 M NaCl, 10 mM Chaps,
5 mM 2-mercaptoethanol, and 10% glycerol) with 10 mM
imidazole, with 7 column volumes of buffer A containing
25 mM of imidazole, and with 7 column volumes of buffer
A with 10 mM imidazole. Solubilized extracts containing
WT full-length IN were filtered through 0.45-m filters and
applied to the column. Bound proteins were washed with 8
column volumes of buffer A containing 25 mM imidazole
or until baseline and then eluted with 9.4 column volumes of
a 10 to 500 mM imidazole gradient in buffer A, collecting
2.5-mL fractions. Aliquots of the fractions were analyzed by
SDS–PAGE and for strand-transfer activity in an oligonu-
cleotide-based assay (see below). Selected fractions were
pooled and diluted to 0.4 M NaCl with buffer C (50 mM
Hepes pH 7.4, 1 mM DTT, 2 mM Chaps, 10% glycerol).
The heparin column–FPLC (5 mL) was sequentially equil-
ibrated with 4 column volumes of buffer C containing 0.4 M
NaCl, with 2 column volumes of buffer C containing 2 M
NaCl and, with 5 0.4 M NaCl, with 2 column volumes of
buffer C containing 2 M NaCl and, with 5 the Ni2-NTA
column were loaded onto the heparin column and eluted
with 7 column volumes of a 0.4 to 2 M NaCl gradient in
buffer C (2.5-mL fractions). Aliquots of the fractions were
analyzed by SDS–PAGE and for strand-transfer activity in
an oligonucleotide-based assay (see below).
Size-exclusion chromatography
Solubilized extracts of WT IN and C209 IN (correspond-
ing to 2 L of culture) were bound in batch to 2 mL of
Ni2-NTA resin and step-eluted with 5 mL of washing
buffer containing 100 and 250 mM imidazole and dialyzed
at 4°C for 6–8 h against 50 mM Hepes, pH 8.0, 1 M NaCl,
1.5 mM DTT, 2 mM Chaps, 10 M ZnCl2, and 10%
glycerol. Proteins were concentrated to 250 L by centricon
columns (YM-10: 10,000 molecular weight cut-off); 0.5 mg
of each IN protein (250 L) was applied to a S200 10/30 gel
filtration column (Pharmacia) preequilibrated with 50 mM
Hepes, pH 8.0, 400 mM KCl, 1.5 mM DTT, 2 mM Chaps,
and 10% glycerol; 0.275-mL fractions were collected. The
column was standardized using gel filtration molecular
weight markers (Sigma): thyroglobulin (669 kDa), apofer-
ritin (443 kDa), alcohol dehydrogenase (150 kDa), bovine
serum albumin (66 kDa), and carbonic anhydrase (29 kDa).
Integration assays
3-processing and strand-transfer reactions contained 0.5
pmol of labeled substrate and reaction buffer containing 20
mM morpholineethanesulfonic acid (MES, pH 6.2), 100
mM KCl, 10 mM MnCl2, 10 mM DTT, and 10% glycerol,
unless otherwise indicated (Jonsson et al., 1993). The reac-
tion conditions (35 L) for two-end integration reactions
(Yang and Roth, 2001) were the same as those for 3-
processing and strand-transfer reactions except that 200 mM
KCl was added in the presence of 1 pmol of U5 substrate
and 1.2 g of target plasmid DNA. Oligonucleotide sub-
strates were labeled at the 5 end by T4 polynucleotide
kinase and mixed with the complementary strand at a ratio
of 1:2 (labeled oligonucleotide vs complementary strand) in
100 mM NaCl. The oligonucleotides were annealed by
heating for 3 min at 95°C and then cooled to room temper-
ature. Complementation assays were performed by preincu-
bating the IN 1-105 with the U5 substrate for 5 min on ice.
IN 106–404 was added, followed by incubation at 37°C for
5 min. When assaying the full-length IN protein, the U5
LTR substrate was preincubated with aliquots of the protein
for 5 min on ice followed by addition of target DNA
plasmid and KCl and the reactions were incubated at 37°C
for 2 h. Reactions were stopped by the addition of 10 mM
EDTA (pH 8.0)–0.5% SDS and 100 g/mL of proteinase K
at 37°C for 1 h. Reaction products were visualized by
electrophoresis on a 1% agarose gel and autoradiography of
dried gels.
Western blot
Western blots were performed using anti-MuLV IN an-
tibody (rabbit 4, bleed 5) (Tanese et al., 1986).
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